Table 3.
Univariate statistical analysis results for serum factors
| Serum factor |
Reference normals Median (Quartiles) |
Benign subjects Median (Quartiles) |
Malignancies Median (Quartiles) |
p valuesa) |
|
|---|---|---|---|---|---|
| KWb) | WRSc) | ||||
| EGF | 44.58 (28.04–56.69) | 3.24 (0.23–5.16) | 2.26 (0.02–5.01) | <0.001 | 0.706 |
| Eotaxin | 20.9 (16.0–33.9) | 16.1 (12.9–28.5) | 18.3 (11.1–24.1) | 0.145 | 0.848 |
| G-CSF | 162 (107–213) | 212 (152–251) | 236 (125–287) | 0.200 | 0.482 |
| HGF | 204 (148.9–248) | 149 (99–247) | 103 (67–178) | 0.002 | 0.033 |
| IL-12 p40 | 55.9 (35.0–66.4) | 74.8 (46.8–06.6) | 59.5 (34.5–84.1) | 0.263 | 0.297 |
| IL-13 | 3.05 (0.30–6.43) | 3.47 (0.24–7.89) | 4.27 (2.13–6.76) | 0.579 | 0.410 |
| IL-15 | 1.04 (0.42–2.14) | 0.86 (0.18–1.39) | 0.63 (0.14–1.66) | 0.536 | 0.749 |
| IL-1a | 0.76 (0.16–7.15) | 1.01 (0.16–8.51) | 0.76 (0.16–8.67) | 0.940 | 0.772 |
| IL-4 | 1.47 (0.68–2.37) | 1.21 (0.71–2.48) | 1.07 (0.62–2.51) | 0.869 | 0.790 |
| IL-5 | 2.19 (1.88–2.43) | 2.65 (2.22–4.42) | 2.19 (1.88–2.50) | 0.009 | 0.018 |
| IL-6 | 5.87 (3.75–8.26) | 5.94 (4.46–8.14) | 6.48 (5.10–8.16) | 0.628 | 0.413 |
| IL-8 | 3.91 (3.49–4.19) | 3.04 (2.65–3.32) | 3.08 (2.71–4.51) | 0.001 | 0.354 |
| IP-10 | 4.67 (2.97–7.11) | 8.91 (5.79–3.34) | 8.22 (4.45–1.98) | 0.017 | 0.655 |
| MIG | 11.5 (6.1–15.8) | 12.6 (9.3–20.2) | 13.7 (11.5–23.6) | 0.149 | 0.424 |
| MIP-1a | 17.1 (11.4–29.1) | 14.4 (10.1–25.2) | 18.1 (8.7–27.6) | 0.897 | 0.941 |
| RANTES | 20 200 (11 600–0 200) | 4800 (3500–700) | 6300 (4400–10 300) | <0.001 | 0.430 |
| TNF-RI | 299 (194–355) | 338 (251–469) | 296 (194–465) | 0.339 | 0.322 |
| TNF-RII | 236 (108–383) | 368 (233–490) | 278 (181–478) | 0.082 | 0.610 |
| TNFα | 12.12 (6.56–21.86) | 6.87 (5.65–10.26) | 7.18 (4.44–11.19) | 0.078 | 0.733 |
a)
p-values in bold are statistically significant at adjusted alpha = 0.01.
b)
KW test of overall equality among all three groups.
c)
WRS test (two-sided), comparing malignancies to benign subjects only.